Pancreatic Cancer Research

ResearcherUniversity of Southern CaliforniaActive in the last 2 years

Yingxiao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0265-326X; OpenAlex author ID A5066337260; NIH RePORTER profile ID 8661093. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
1
Labs led
1
Collaborators
25
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 grant · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 6

  1. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  2. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  3. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  4. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  5. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  6. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-4545↗

Grants 1

  1. Multiplex FRET Imaging of Kinase-Epigenome Interregulations in Live Cancer Cells R33CA204704↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Max Nobis · 3 shared papers, 2013–2021 · strength 0.16
  2. Jennifer P. Morton · 3 shared papers, 2013–2021 · strength 0.16
  3. Owen James Sansom · 3 shared papers, 2013–2021 · strength 0.16
  4. Paul Timpson · 3 shared papers, 2013–2021 · strength 0.16
  5. Claire Vennin · 2 shared papers, 2018–2021 · strength 0.14
  6. Kendelle Joan Murphy · 2 shared papers, 2018–2021 · strength 0.14
  7. Marina Pajic · 2 shared papers, 2018–2021 · strength 0.14
  8. David Herrmann · 2 shared papers, 2018–2021 · strength 0.14
  9. James R. W. Conway · 2 shared papers, 2018–2021 · strength 0.14
  10. Ashleigh Parkin · 1 shared paper, 2021 · strength 0.08
  11. Michael Tayao · 1 shared paper, 2021 · strength 0.08
  12. Jaswinder Singh Samra · 1 shared paper, 2021 · strength 0.08
  13. Angela S. Y. Chou · 1 shared paper, 2021 · strength 0.08
  14. Shona Ritchie · 1 shared paper, 2021 · strength 0.08
  15. Thomas R. Cox · 1 shared paper, 2021 · strength 0.08
  16. Amber L. Johns · 1 shared paper, 2021 · strength 0.08
  17. Cecilia R. Chambers · 1 shared paper, 2021 · strength 0.08
  18. Roger J. Daly · 1 shared paper, 2021 · strength 0.08
  19. Sean Michael Grimmond · 1 shared paper, 2021 · strength 0.08
  20. Anthony James Gill · 1 shared paper, 2021 · strength 0.08
  21. Brooke Pereira · 1 shared paper, 2021 · strength 0.08
  22. Australian Pancreatic Cancer Genome Initiative (APGI) · 1 shared paper, 2021 · strength 0.08
  23. Andrew Victor Biankin · 1 shared paper, 2021 · strength 0.08
  24. Thomas R. Jeffry Evans · 1 shared paper, 2013 · strength 0.03
  25. Kurt I. Anderson · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.